Ionis Pharmaceuticals: A letter to the Angelman syndrome community.
Ionis addresses community questions following the ASPIRE trial results, reaffirming its commitment to obudanersen (ION582) through the HALOS, REVEAL, and CHAMPION trials
Ionis addresses community questions following the ASPIRE trial results, reaffirming its commitment to obudanersen (ION582) through the HALOS, REVEAL, and CHAMPION trials
Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.